换一批
换一批Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
作者：
主题词
医学科学研究中心(Academic Medical Centers);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);地塞米松(Dexamethasone);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);男(雄)性(Male);中年人(Middle Aged);多发性骨髓瘤(Multiple Myeloma);预后(Prognosis);缓解诱导(Remission Induction);回顾性研究(Retrospective Studies);存活率(Survival Rate);沙立度胺(Thalidomide)
DOI
10.1007/s00432-020-03323-6
PMID
32683487
发布时间
2021-01-28
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
